Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif.
about
Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathyAdvanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE)Inhibition of hyphal growth of azole-resistant strains of Candida albicans by triazole antifungal agents in the presence of lactoferrin-related compoundsExpression of recombinant human lysozyme in egg whites of transgenic hensGlycoprotein expression in human milk during lactation.FEEL-1 and FEEL-2 are endocytic receptors for advanced glycation end products.Animal antimicrobial peptides: an overview.The AGE-receptor in the pathogenesis of diabetic complications.Advanced glycation and the immune system: stimulation, inhibition or both?Diabetic vascular dysfunction: links to glucose-induced reductive stress and VEGF.Identification of increased amounts of eppin protein complex components in sperm cells of diabetic and obese individuals by difference gel electrophoresisReduced acute vascular injury and atherosclerosis in hyperlipidemic mice transgenic for lysozyme.Purification and Characterization of Recombinant Human Lysozyme from Eggs of Transgenic ChickensEffects of advanced glycation end products on ezrin-dependent functions in LLC-PK1 proximal tubule cells.Localization of the ezrin binding epitope for glycated proteins.Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: relationship to tissue AGEsAGE restriction in diabetes mellitus: a paradigm shift.A perspective on the Maillard reaction and the analysis of protein glycation by mass spectrometry: probing the pathogenesis of chronic diseaseMolecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins.Depletion of reactive advanced glycation endproducts from diabetic uremic sera using a lysozyme-linked matrix.Molecular strategies to prevent, inhibit, and degrade advanced glycoxidation and advanced lipoxidation end products.Advanced glycation end-products: a common pathway in diabetes and age-related erectile dysfunction.Non-enzymatic glycation and glycoxidation protein products in foods and diseases: an interconnected, complex scenario fully open to innovative proteomic studies.Multifunctional iron bound lactoferrin and nanomedicinal approaches to enhance its bioactive functions.Study on the expression of human lysozyme in oviduct bioreactor mediated by recombinant avian adeno-associated virus.Amelioration of oxidant stress by the defensin lysozyme.Advanced glycation end-products and atherosclerosis.Atherogenesis and advanced glycation: promotion, progression, and prevention.From bacterial killing to immune modulation: Recent insights into the functions of lysozyme.In vitro effect of advanced glycation end-products on human polymorphonuclear superoxide production.A luminescent G-quadruplex-selective iridium(iii) complex for the label-free detection of lysozymeRole of advanced glycation end products in mobility and considerations in possible dietary and nutritional intervention strategies
P2860
Q24682750-133EF53F-C001-407A-B9B7-D7B7E9DE8539Q28366662-0D45CCFD-436C-4838-894F-80522737E98BQ28379616-293CC23C-BDD6-4BA2-BDCE-3AAFCCF6123AQ28543585-289C4268-AE5B-482C-BF4E-9582136B5211Q30388479-D1D20063-B681-49B4-AD41-0F549CB28C82Q30873486-5EDC86BF-D1C0-4CBE-90E9-C0F6C987693EQ33638713-2571A9B2-C185-406A-8822-5532DB53BDB0Q34470639-86C784D8-B813-4C42-9071-543582B9DF91Q34570629-DA679AC7-E99A-426D-A1D5-E7B51F1B77DFQ34733351-F2093F4F-FD29-45A0-A8C7-A3EC84E7730CQ35144136-AE1C8981-DBBF-450A-9A52-7CA7D415D798Q35221896-AD45D35C-50E2-45AC-B1FB-DFFAF6919DA1Q35880503-03FFABCE-04AD-442F-A537-587786B727DFQ36203985-25FE147E-A936-48A0-868B-1902019AC02BQ36203989-E73C970C-13CF-4141-AD23-E7C9DCF0968CQ36437790-196A679D-8D0C-47DF-91BA-511205EE1BE5Q37003623-C77213AD-C2F9-4DA2-86ED-47F5BACF3A18Q37097143-B3FD6A14-982E-443B-84B7-0EFF9F171719Q37308593-6BD0CC1C-E0BA-4EA8-9DBE-A456FDFD2945Q37371152-0E4C9805-9BBE-42CA-846B-2CA270734010Q38096444-F420B59B-D214-41AC-8047-E1014198A9E6Q38118993-9DC6475F-FF89-4720-B875-82613DF17F89Q38151611-6BE101E3-566A-47B2-A4B7-CFAE23140036Q38504324-A8373407-7377-4AF4-8037-BB049C2B36EAQ40275256-EF22F6B6-E33D-4BE3-BB99-F8B333A11C00Q40346041-6361369D-B285-4A29-96BA-DB5E2A52E321Q41250355-5833CF3A-B2F4-4733-B075-E05CBFFA1D9EQ41500579-9B9583DA-C099-4466-90D0-AAF440B291DBQ42047981-3CD8ABC9-9DB4-4654-BDD8-80FDD4C6E50DQ43923373-ADA2B8B2-9793-4875-9A33-4C06D6D2221BQ57552213-F6E4A192-0A9D-4E31-B8CC-972A200988AFQ58577346-5A84EB64-79A8-41CB-99A6-32F99ECEECD9
P2860
Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh-hant
name
Antibacterial activity of lyso ...... proteins to a conserved motif.
@en
Antibacterial activity of lyso ...... proteins to a conserved motif.
@nl
type
label
Antibacterial activity of lyso ...... proteins to a conserved motif.
@en
Antibacterial activity of lyso ...... proteins to a conserved motif.
@nl
prefLabel
Antibacterial activity of lyso ...... proteins to a conserved motif.
@en
Antibacterial activity of lyso ...... proteins to a conserved motif.
@nl
P2093
P2860
P356
P1433
P1476
Antibacterial activity of lyso ...... proteins to a conserved motif.
@en
P2093
P2860
P2888
P304
P356
10.1038/NM1095-1057
P407
P577
1995-10-01T00:00:00Z
P6179
1025051890